Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.
No-Receipt date
2014-02066 - 15/07/2014
No-Filing date
20140401380 - 15/07/2014
No-Granting date
3083861 - 22/07/2014
No-EPO application date
09716778.7 - 04/03/2009
No-EPO granting date
2259800 - 07/05/2014
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
7/2014 - 01/09/2014
Expiration date
05/03/2029
Kind of title
Validation of European Patent
Legal status
NOT VALID
Priorities
EP0815232605/03/2008/EP
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61K 31/5377
A61K 45/06
A61P 35/00
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
542122
NOVARTIS AG
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND
Inventors
Code
Firstname
Surname
1304373
GARCIA-ECHEVERRIA, CARLOS
1304374
MAIRA, SAUVEUR-MICHEL
Representatives
Code
Firstname
Surname
Address
Town
Zip
3335
ANDRONIKI
KIAGIA
STOURNARA 37
ATHINA (ATTIKIS)
10682
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
7916
CHRISTINA-ISMINI
VAGIANOU KOSTOPOULOU
STOURNARI 37
ATHINA (ATTIKIS)
10682
GREECE
Owners History
Title Instruments
Date
Operation
Descreption
10/5/2017 12:00:00 AM
Έκπτωση Κύριων Τίτλων (79602)
ΕΚΠΤΩΣΕΙΣ 09/2017 Αρ. Πρωτ. Γ.Δ. 1702 / 05-10-2017
Payments history
8 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).